We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+18.8%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$2.68B
AUM Growth
+$421M
Cap. Flow
+$302M
Cap. Flow %
11.29%
Top 10 Hldgs %
68.02%
Holding
83
New
12
Increased
16
Reduced
6
Closed
11

Top Buys

Rank Stock Value
1
ALEC icon
Alector
ALEC
+$68.6M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$52.4M
3
RLAY icon
Relay Therapeutics
RLAY
+$34.9M
4
RCUS icon
Arcus Biosciences
RCUS
+$32.5M
5
JANX icon
Janux Therapeutics
JANX
+$31.4M

Top Sells

Rank Stock Value
1
ELDN icon
Eledon Pharmaceuticals
ELDN
+$11.9M
2
AMTI
Applied Molecular Transport Inc. Common Stock
AMTI
+$10.5M
3
NGNE icon
Neurogene
NGNE
+$8.45M
4
ACIU icon
AC Immune
ACIU
+$6.91M
5
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$5.09M

Sector Composition

Rank Sector Weight
1 Healthcare 98.93%
2 Financials 0.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNCE
76
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
– –
-2,825
Closed -$573K
AMTI
77
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
– –
-239,443
Closed -$10.5M
CDAK
78
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
– –
-115,195
Closed -$1.74M
MTCR
79
DELISTED
Metacrine, Inc. Common Stock
MTCR
– –
-62,207
Closed -$386K
FLACU
80
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
– –
-200,000
Closed -$2.03M
LOGC
81
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
– –
-688,700
Closed -$5.01M
CHFW.U
82
DELISTED
Consonance-HFW Acquisition Corp. Units, each consisting of one Class A Ordinary Share, and one-third
CHFW.U
– –
-200,000
Closed -$1.95M
VINCW
83
DELISTED
Vincerx Pharma, Inc. Warrant
VINCW
– –
-150,000
Closed -$2.9M
1 2 3
4

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q2 2021 Portfolio in Review

As of Q2 2021, EcoR1 Capital held 83 positions worth $2.68B, up 19% from $2.25B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

EcoR1 Capital deployed $302M of net new capital in Q2 2021, opening 12 new positions and adding to 16 existing holdings. Its largest new stake was Janux Therapeutics: 1,411,975 shares worth $35.2M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Neurogene, an estimated $8.45M trimmed.

  • EcoR1 Capital's largest Q2 2021 buy was Janux Therapeutics: 1,411,975 shares worth $35.2M.
  • EcoR1 Capital added most to Alector in Q2 2021, an estimated $68.6M increase.
  • EcoR1 Capital's biggest Q2 2021 reduction was Neurogene, cutting an estimated $8.45M.
  • EcoR1 Capital fully exited Eledon Pharmaceuticals in Q2 2021, selling an estimated $11.9M.
  • EcoR1 Capital's ten largest holdings make up 68% of its $2.68B portfolio in Q2 2021.
  • EcoR1 Capital opened 12 new positions and closed 11 in Q2 2021.
  • EcoR1 Capital's portfolio value rose 19% quarter-over-quarter to $2.68B.

Based on EcoR1 Capital's 13F filing for Q2 2021, filed 16 Aug 2021.